Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 324-331

  Wong, Shekman L ^a   Drajesk, Jeffrey ^a   Chang, Min ^a   Lanni, Carmine ^a   Witt, Galen ^a   Hansen, Robert ^a   Awni, Walid M ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; PLACEBO; THROMBOXANE B2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ARACHIDONATE 5-LIPOXYGENASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROXYUREA; MALE; REFERENCE VALUES;

EID: 0031892899     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90164-3     Document Type: Article

References (13)

1. Samuelsson B. Leukotriene: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
2. Batt DG. 5-lipoxygenase inhibitors and their antiinflammatory activities. Prog Med Chem 1992;29:1-63.
3. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
4. 4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980;286:264-5.
5. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchiole. Nature 1980;288:484-6.
6. Schellenberg RR, Foster A. In vitro responses of human asthmatic airway and pulmonary vascular smooth muscle. Int Arch Allergy Immunol 1984;75: 237-41.
7. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC, et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-9.
8. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
9. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, et al. The effects of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119:1059-66.
10. Israel E, Cohn J, Dube L, Drazen JM, Zileuton Clinical Trial Group. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma, a randomized controlled trial. JAMA 1996;275:931-6.
11. Wong SL, Drajesk J, Chang M, Witt G, Awni WM. Dose-proportional pharmacokinetics of a second generation 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers. Biopharm Drug Dispos [in press].
12. Awni WM, Braeckman RA, Cavanaugh JH, Locke CS, Linnen PJ, Granneman GR, et al. The pharmacokinetics and pharmacodynamics interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in healthy volunteers. Clin Pharmacokinet 1995;29(suppl 2):112-24.
13. Beal SL, Sheiner LB. NONMEM users guide, part I: users basic guide, NONMEM version IV (level 1.0) project group. San Francisco: University of California, San Francisco; 1989.